Cell of origin in biliary tract cancers and clinical implications
Affiliation
Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, ManchesteIssue Date
2021
Metadata
Show full item recordAbstract
Biliary tract cancers (BTCs) are aggressive epithelial malignancies that can arise at any point of the biliary tree. Albeit rare, their incidence and mortality rates have been rising steadily over the past 40 years, highlighting the need to improve current diagnostic and therapeutic strategies. BTCs show high inter- and intra-tumour heterogeneity both at the morphological and molecular level. Such complex heterogeneity poses a substantial obstacle to effective interventions. It is widely accepted that the observed heterogeneity may be the result of a complex interplay of different elements, including risk factors, distinct molecular alterations and multiple potential cells of origin. The use of genetic lineage tracing systems in experimental models has identified cholangiocytes, hepatocytes and/or progenitor-like cells as the cells of origin of BTCs. Genomic evidence in support of the distinct cell of origin hypotheses is growing. In this review, we focus on recent advances in the histopathological subtyping of BTCs, discuss current genomic evidence and outline lineage tracing studies that have contributed to the current knowledge surrounding the cell of origin of these tumours.Citation
Moeini A, Haber PK, Sia D. Cell of origin in biliary tract cancers and clinical implications. JHEP Rep. 2021;3(2):100226.Journal
JHEP Reports : innovations in hepatologyDOI
10.1016/j.jhepr.2021.100226PubMed ID
33665585Additional Links
https://dx.doi.org/10.1016/j.jhepr.2021.100226Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jhepr.2021.100226
Scopus Count
Collections
Related articles
- Pathogenesis, diagnosis, and management of cholangiocarcinoma.
- Authors: Rizvi S, Gores GJ
- Issue date: 2013 Dec
- The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
- Authors: Chong DQ, Zhu AX
- Issue date: 2016 Jul 19
- Biliary cancer: Utility of next-generation sequencing for clinical management.
- Authors: Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J
- Issue date: 2016 Dec 15
- Gene methylation in gastric cancer.
- Authors: Qu Y, Dang S, Hou P
- Issue date: 2013 Sep 23
- Emerging molecular therapeutic targets for cholangiocarcinoma.
- Authors: Rizvi S, Gores GJ
- Issue date: 2017 Sep